Within a matter of five days, Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) is back with the announcement of another clinical site for its ongoing Investigational Device Exemption (IDE) clinical study of Neuro-Spinal Scaffold. In a press release, the company said that it has added University of Kansas Medical Center in Kansas City as a new site for its study. The company has named Paul Arnold, MD, Professor of Neurosurgery and Vice Chair of Research as Principal Investigator at the site.
Study well-paced
Few days back, Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) had announced the addition of Keck Hospital of University of Southern California as a new site for its clinical trial. Moreover, the company has also announced reopening of enrollment of the subjects that would complete its Neuro-Spinal Scaffold trial meant for severe spinal cord injury (SCI).
The company has already reported excellent results that its study returned in previous two patients. Both the patients have showed improvement in their condition post-implantation of NSS. The company has also received words of appreciation from the Zacks research analyst Jason Napodano. According to whom, the company’s neuro-spinal scaffold clinical trial is moving forward at a remarkable pace.
Zacks’ confidence
He noted that Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) is expected to enroll the remaining three patients for its IDE study during the next few months. It is likely that the news will keep on flowing in this regard over the forthcoming months. Moreover, Napodano anticipated that the company may begin registration study by as early as next year.
The analyst concluded that though the stock of Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) has already witnessed momentum but more room for upside is available in the stock. The stock of the company climbed by 2.04% to $3 during the previous trading session. Also, the average volume of shares stood at 1.18 million.
